Companion Diagnostics
News on companion diagnostics and drug/test co-development.
Burning Rock Biotech, Abbisko Therapeutics Ink CDx Partnership for ABSK091
Burning Rock will use its sequencing platform to identify urothelial carcinoma patients with FGFR alterations, supporting development of Abbisko's drug.
Boundless Bio Raises $105M in Series B Financing
With this funding, the company will advance its three extrachromosomal DNA-targeted therapies and a companion diagnostic into the clinic.
Illumina, Kartos Therapeutics Partner to Develop TP53 Companion Diagnostic
The two companies will codevelop the next-generation sequencing test for Kartos's MDM2 inhibitor, KRT-232, being studied in TP53 wild-type blood cancers.
FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer
The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.